IN8bio, Inc. $INAB Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. lessened its position in shares of IN8bio, Inc. (NASDAQ:INAB) by 96.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 189,894 shares of the company’s stock after selling 5,506,308 shares during the period. Franklin Resources Inc. owned about 0.06% of IN8bio worth $397,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

INAB has been the topic of several research analyst reports. Mizuho set a $4.00 price objective on IN8bio in a research note on Monday, October 13th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of IN8bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $92.00.

IN8bio Trading Up 0.6%

INAB opened at $1.78 on Tuesday. The business’s 50 day moving average is $1.95 and its 200-day moving average is $2.28. The stock has a market cap of $7.51 million, a PE ratio of -0.33 and a beta of 0.02. IN8bio, Inc. has a twelve month low of $1.53 and a twelve month high of $12.53.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.35. As a group, analysts forecast that IN8bio, Inc. will post -0.56 EPS for the current year.

IN8bio Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.